Skip to content
15% off your first order15% off your first order

GLP-3R vs Tirzepatide

GLP-3R and Tirzepatide are both incretin-based research peptides studied for metabolic regulation and administered subcutaneously in research protocols. GLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors, while Tirzepatide is studied as a dual agonist at the GLP-1 and GIP receptors. The glucagon receptor component is the main mechanistic distinction, and research explores whether it contributes an energy expenditure effect alongside appetite signaling. GLP-3R has been studied for body weight reduction in obesity, glycemic control in type 2 diabetes, and liver fat in metabolic dysfunction-associated steatotic liver disease. Tirzepatide has been evaluated in multiple phase 3 trials for glycemic control, weight reduction and maintenance, and a head-to-head comparison with semaglutide.